SCHEMBL5423015

SCHEMBL5423015

Cc1cc(Br)ccc1C(N)=O.O=S(=O)(O)/C=C/c1cccc(Cl)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STAT3 P40763 1/20 0.45
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
CYP1A2 P05177 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
NPC1 O15118 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C19 P33261 1/20 0.43
RAB9A P51151 1/20 0.43
NFE2L2 Q16236 4/20 0.42
FLT1 P17948 1/20 0.42
FLT4 P35916 1/20 0.42
KDR P35968 1/20 0.42
CYP2C9 P11712 1/20 0.41
PTGES2 Q9H7Z7 3/20 0.40
GPR52 Q9Y2T5 1/20 0.40
CA12 O43570 1/20 0.39
CA9 Q16790 1/20 0.39
MAOB P27338 2/20 0.38
MAOA P21397 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27738946 1.00 STAT3 (0.45) STAT3MEN1KMT2ACYP1A2SMN1; SMN2
SCHEMBL27717781 0.91 CYP1A2 (0.46) MEN1KMT2ACYP1A2SMN1; SMN2NPC1
SCHEMBL5417301 0.91 CYP1A2 (0.46) MEN1KMT2ACYP1A2SMN1; SMN2NPC1
SCHEMBL5414597 0.90 CYP1A2 (0.46) STAT3MEN1KMT2ACYP1A2SMN1; SMN2
SCHEMBL27717768 0.90 CYP1A2 (0.46) STAT3MEN1KMT2ACYP1A2SMN1; SMN2
SCHEMBL5417526 0.88 PTGES2 (0.49) MEN1KMT2ACYP1A2SMN1; SMN2NPC1
SCHEMBL27738934 0.88 PTGES2 (0.49) MEN1KMT2ACYP1A2SMN1; SMN2NPC1
SCHEMBL27739136 0.88 PTGS2 (0.43) MEN1KMT2ASMN1; SMN2RAB9ANFE2L2
SCHEMBL5411190 0.88 PTGS2 (0.43) MEN1KMT2ASMN1; SMN2RAB9ANFE2L2
SCHEMBL5416906 0.86 PTGS2 (0.41) FLT1FLT4KDRPTGES2CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101268042-A Styryl sulfonamides, their preparation and use as pharmaceutical agents HOFFMANN LA ROCHE (CH) 2008-09-17 CN claimed
US-7208526-B2 For example, (E)-2-(4-Chloro-phenyl)-ethenesulfonic acid 2,4-dichloro-benzoylamide; for use in the control or prevention of illnesses such as cancer; antitumor agents HOFFMANN-LA ROCHE INC. (US) 2007-04-24 US claimed
US-20060270874-A1 Styrylsulfonamides HOFFMANN-LA ROCHE INC. 2006-11-30 US claimed
CN-101268042-A Styryl sulfonamides, their preparation and use as pharmaceutical agents HOFFMANN LA ROCHE (CH) 2008-09-17 CN disclosed
US-7208526-B2 For example, (E)-2-(4-Chloro-phenyl)-ethenesulfonic acid 2,4-dichloro-benzoylamide; for use in the control or prevention of illnesses such as cancer; antitumor agents HOFFMANN-LA ROCHE INC. (US) 2007-04-24 US disclosed
US-20060270874-A1 Styrylsulfonamides HOFFMANN-LA ROCHE INC. 2006-11-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060270874-A1 Styrylsulfonamides STS, SULT1E1, BRCA1 STAT3 4488/4885MEN1 1331/4885KMT2A 2935/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.